News Releases

Filter News Releases by year:
2024 | 2023 | 2022 | 2021 | 2020

17 Results

January 2024

Switching to Vegan or Ketogenic Diet Rapidly Impacts Immune System

January 30, 2024

Researchers at the National Institutes of Health observed rapid and distinct immune system changes in a small study of people who switched to a vegan or a ketogenic (also called keto) diet. Scientists closely monitored various biological responses of people sequentially eating vegan and keto diets for two weeks, in random order.

December 2023

Statement: Antibody Reduces Allergic Reactions to Multiple Foods in NIH Trial

December 19, 2023

A monoclonal antibody treatment significantly increased the amounts of multiple common foods that food-allergic children and adolescents could consume without an allergic reaction, according to a planned interim analysis of an advanced clinical trial. The trial is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

August 2023

Severe COVID-19 May Lead to Long-Term Innate Immune System Changes

August 18, 2023

Severe COVID-19 may cause long-lasting alterations to the innate immune system, the first line of defense against pathogens, according to a small study funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. These changes may help explain why the disease can damage so many different organs and why some people with long COVID have high levels of inflammation throughout the body. The findings were published online today in the journal Cell

June 2023

Screening Newborns for Deadly Immune Disease Saves Lives

June 20, 2023

Introducing widespread screening of newborns for a deadly disease called severe combined immunodeficiency, or SCID, followed by early treatment boosted the five-year survival rate of children with the disorder from 73% before the advent of screening to 87% since, researchers report. Among children whose disease was suspected because of newborn screening rather than illness or family history, 92.5% survived five years or more after treatment.

May 2023

NIH Researchers Uncover New Details on Rare Immune Disease

May 3, 2023

In an 11-year study, researchers at the National Institutes of Health have further characterized idiopathic CD4 lymphocytopenia (ICL), a rare immune deficiency that leaves people vulnerable to infectious diseases, autoimmune diseases and cancers. Researchers observed that people with the most severe cases of ICL had the highest risk of acquiring or developing several of the diseases associated with this immune deficiency. This study, published in the New England Journal of Medicine, was led by Irini Sereti M.D., M.H.S. and Andrea Lisco, M.D., Ph.D.

March 2023

NIH Researchers Discover New Autoinflammatory Disease, Suggest Target for Potential Treatments

March 28, 2023

Scientists have identified an autoinflammatory disease caused by mutations in the LYN gene, an important regulator of immune responses in health and disease. Named Lyn kinase-associated vasculopathy and liver fibrosis (LAVLI), the identification sheds light on how genes linked to certain illnesses can potentially be targets for treatment by repurposing existing drugs. The research, published in Nature Communications, was led by Adriana A. de Jesus, M.D. Ph.D., and Raphaela Goldbach-Mansky, M.D., M.H.S.

October 2022

Monoclonal Antibody Improves Cat Allergen Immunotherapy

October 11, 2022

An experimental approach to enhancing a standard cat allergy treatment made it more effective and faster acting, and the benefits persisted for a year after treatment ended, a study supported by the National Institutes of Health has found. The findings were published Monday in the Journal of Allergy and Clinical Immunology

June 2022

Food Allergy Is Associated with Lower Risk of SARS-CoV-2 Infection

June 1, 2022

A National Institutes of Health-funded study has found that people with food allergies are less likely to become infected with SARS-CoV-2, the virus that causes COVID-19, than people without them. In addition, while previous research identified obesity as a risk factor for severe COVID-19, the new study has identified obesity and high body mass index (BMI) as associated with increased risk for SARS-CoV-2 infection. In contrast, the study determined that asthma does not increase risk for SARS-CoV-2 infection.

August 2021

NIH Launches Study of Extra COVID-19 Vaccine Dose in People with Autoimmune Disease

August 27, 2021

The National Institutes of Health has begun a clinical trial to assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune disease who did not respond to an original COVID-19 vaccine regimen. The trial also will investigate whether pausing immunosuppressive therapy for autoimmune disease improves the antibody response to an extra dose of a COVID-19 vaccine in this population.

May 2021

Gene Therapy Restores Immune Function in Children with Rare Immunodeficiency

May 11, 2021

An investigational gene therapy can safely restore the immune systems of infants and children who have a rare, life-threatening inherited immunodeficiency disorder, according to research supported in part by the National Institutes of Health.

NIH Statement on World Asthma Day 2021

May 5, 2021

On World Asthma Day, the National Institutes of Health reaffirms its commitment to research to improve the lives of people with asthma. More than 25 million people in the United States have asthma, including 5.1 million children, according to the Centers for Disease Control and Prevention. This chronic lung disease can reduce quality of life, contributes to considerable emotional and financial stress, and is a major contributing factor to missed time from school and work.

April 2021

COVID-19 Vaccine Responses to be Studied in People with Immune Deficits

April 23, 2021

A study assessing how people with immune system deficiencies or dysregulations respond to COVID-19 vaccination has begun enrolling participants at the National Institutes of Health Clinical Center in Bethesda, Maryland. The single-site study is led by researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and aims to enroll 500 people, 400 with primary or secondary immune system disorders and 100 without such conditions. 

NIH Establishes New Childhood Asthma Clinical Research Network

April 23, 2021

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded $10 million in first-year funding to establish a clinical research network called Childhood Asthma in Urban Settings (CAUSE). This nationwide network will conduct observational studies and clinical trials to improve understanding of asthma and develop treatment and prevention approaches tailored to children of low-income families living in urban communities. NIAID intends to provide approximately $70 million over seven years to support the CAUSE network.

March 2021

NIH Study of Early Predictors, Mechanisms of Food Allergy and Eczema has Begun

March 19, 2021

A study to identify prenatal and early childhood markers of high risk for food allergy and atopic dermatitis, or eczema, as well as biological pathways that lead to these conditions, has begun. The observational study of children from birth to age 3 years will examine the origins of allergic disease by integrating interdisciplinary analyses of data from more than 260 biological and environmental samples and survey responses from each of 2,500 families.

August 2020

NIH-Supported Scientists Demonstrate How Genetic Variations Cause Eczema

August 14, 2020

New NIH-supported research shows how two common variations in the KIF3A gene cause an impaired skin barrier that allows increased water loss from the skin.

May 2020

NIH Statement on World Asthma Day 2020

May 5, 2020

On World Asthma Day, the NIH raises awareness about this disease, the people affected, and the biomedical research that improves prevention and treatment. 

January 2020

New Multiple Sclerosis Treatment Trial Compares Stem Cell Transplantation to Best Available Drugs

January 7, 2020

A clinical trial has begun testing an experimental stem cell treatment against the best available biologic therapies for severe forms of relapsing multiple sclerosis (MS). The trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will compare the safety, efficacy and cost-effectiveness of the two therapeutic approaches.